Industry News
Pharmaceutical Industry News
The company is lowering the annual…
The company is lowering the annual list price of Tryngolza from $595,000 to $40,000 ahead of an anticipated expansion into the much larger market of severe hypertriglyceridemia.
The FDA has approved Denali…
The FDA has approved Denali Therapeutics’ enzyme replacement therapy for a genetic lysosomal storage disease after a string of high-profile rejections for rare disease candidates.
Why pharma marketers pulling back…
Why pharma marketers pulling back on tracking are seeing hidden costs, and what a more sustainable path forward looks like
Novartis is facing a class-action…
Novartis is facing a class-action lawsuit alleging it shared, without patients’ consent, sensitive health information it collected from visitors to its consumer-facing branded drug websites.
Takeda is setting the stage for a…
Takeda is setting the stage for a sweeping new round of restructuring, aiming to streamline operations to bankroll upcoming drug launches and late-stage pipeline development.
Biogen will hand Alteogen $20…
Biogen will hand Alteogen $20 million upfront for help developing subcutaneous formulations of two unnamed biologics using Alteogen’s delivery technology.
While touting the uptake of new…
While touting the uptake of new drugs Hernexeos and Jascayd in the U.S., Boehringer Ingelheim's chairman leveled criticism of regulatory red tape in Europe, where the treatments have yet to be approved.
With key expansions coming to…
With key expansions coming to fruition on either side of the pond, specialist CDMO Hovione is making sure that drugmakers can access its particle engineering expertise across multiple geographies.
UCB will build a new manufacturing…
UCB will build a new manufacturing facility near its U.S. headquarters in Atlanta, Georgia. It will become the first major manufacturing facility in the U.S. for the rapidly growing Belgium-based company and will produce biologics. The
Forward-looking precision:…
Forward-looking precision: How pharma can engage providers at the moments that shape care decisions
Abivax has appointed Michael…
Abivax has appointed Michael Nesrallah as its chief commercial officer, putting one of the people who turned Entyvio into a blockbuster in charge of preparations for its ulcerative colitis launch.
The FDA this month issued a…
The FDA this month issued a warning letter to ImmunityBio regarding promotional statements about cancer drug Anktiva that the agency claims are “false or misleading.”
The new initiative stars Jodie…
The new initiative stars Jodie Sweetin and John Stamos, who played Stephanie Tanner and her Uncle Jesse on “Full House,” having a candid chat about starting colorectal cancer screening at age 45.
The company is winding down the…
The company is winding down the sale of a handful of its insulin products across different European countries, according to the European Medicines Agency.
Karyopharm has provided mixed…
Karyopharm has provided mixed results from a phase 3 trial testing Xpovio in combination with Incyte and Novartis’ blockbuster Jakafi in patients with first-line myelofibrosis. The company will discuss the results with the FDA in
Despite policy uncertainties in…
Despite policy uncertainties in recent years, WuXi Biologics’ emphasis on its U.S. operations continued to pay off in 2025, with the States accounting for a major portion of the record number of projects the CRDMO
Gilead has partnered with digital…
Gilead has partnered with digital health company Manta Cares to get tools for navigating lung and breast cancer care pathways to patients.
Wilmington PharmaTech, a CDMO…
Wilmington PharmaTech, a CDMO specializing in churning out complex custom APIs for small molecules, will drop $50 million in a move to double the current production capacity at its Delaware facility.
India’s Strides Pharma issued a…
India’s Strides Pharma issued a voluntary recall for 89,592 bottles of liquid ibuprofen pain medication for children following reports of contamination.
The Supreme Court denied Takeda…
The Supreme Court denied Takeda and Lilly's bid to stop the case from moving forward. If the drugmakers come up short in defending against the RICO allegations, the companies could be on the line for